Today, the European Commission unveiled the Critical Medicines Act aimed at strengthening the resilience of Europe’s pharmaceutical supply chains and ensuring equitable access to essential medicines.

While the EHC fully supports the European Commission’s efforts to address medicine shortages and improve the pharmaceutical supply chain, we believe it is essential that the voices of patients with rare diseases are heard and integrated into the final strategy. We stand ready to work together to ensure that the Critical Medicines Act fulfils its potential to safeguard the health and well-being of all patients, particularly those with rare and life-threatening conditions.